Can Wockhardt Hit ₹2,000? SEBI RA Vijay Gupta Sees Potential As US Generics Exit Boosts Momentum

Wockhardt shares rose over 3% on Monday after the company announced that it is exiting its loss-making generics business in the US, as it shifts its focus to new antibiotic drug discovery and insulin portfolios.

Over the past several years, the company's US generic business has experienced losses, amounting to nearly $8 million in FY25 alone. 

SEBI-registered analyst Vijay Kumar Gupta highlighted the strong bullish breakout on the charts as the stock surged above resistance with volumes, signaling renewed momentum. He added that the technical chart shows strength after consolidation, which could mean the possibility of upside continuation if the current uptrend holds. 

On the indicators, Wockhardt is trading well above the Ichimoku cloud, Tenkan & Kijun lines supporting bullish sentiment. The Commodity Channel Index (CCI) stands at 208.73, which is extremely overbought; hence, he cautioned to watch for cooling. But the On-Balance Volume (OBV) is rising again, confirming demand behind the move.

Gupta identified support at ₹1,749, ₹1,712, and resistance between ₹1,880 and ₹1,940 zone (which is the supply region from previous highs) 

In other recent news developments, the company received approvals for two injectable generics from the USFDA, potentially boosting its U.S. revenue stream in FY26. 

Market speculation is also rising that Wockhardt may unlock value via monetization of its hospital vertical. There has been no official statement yet. Gupta also highlighted that the management has hinted at improving debt-service ratios due to increased exports and internal accruals in recent analyst calls. 

Trade Strategy

For traders holding the stock, Gupta suggests keeping the trail stop-loss to ₹1,740 as momentum is intact. For those looking to buy, he recommended waiting for a dip near ₹1,750–₹1,780 with a tight stop loss to consider fresh entries. 

Wockhardt is showing a strong price-volume breakout from the range. If supported by news or earnings upgrades, ₹2,000+ could be on cards in the short term, he concluded.

Wockhardt shares have gained 29% year-to-date (YTD).

For updates and corrections, email newsroom[at]stocktwits[dot]com.